A pilot study of flutamide. a new agent in the treatment of advanced prostatic cancer
Sarfaty, G.A.; Alder, S.J.; McLean, R.G.
Medical Journal of Australia 140(4): 219-221
1984
ISSN/ISBN: 0025-729X PMID: 6694625 Document Number: 240220
Flutamide, a new non-steroidal antiandrogenic agent, was administered in the treatment of five assessable patients with advanced carcinoma of the prostate. Two patients showed significant clinical benefit, one showed a reduction in his requirement for analgesia and two failed to benefit; side-effects were minimal. These results indicate the need for a controlled clinical trial of flutamide in patients with prostatic cancer.
Document emailed within 1 workday
Related Documents
Pummer, K. 1991: Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer Seminars in Oncology 18(5 Suppl 6: 26-28Chime-Udeh, E. 1991: Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2) Connecticut Medicine 55(9): 526-528
Lawson, D.; Moore, M.; Smalley, R. 1980: An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. a pilot study of the Southeastern Cancer Study Group Cancer Clinical Trials 3(4): 293-296
Fosså, S.D.; Miller, A. 1975: Treatment of advanced prostatic cancer Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 95(13): 811-814
Zhang, Y.-F.; Yu, Y.-F.; Lu, S. 2009: Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer Zhonghua Yi Xue Za Zhi 89(22): 1544-1548
Murray, R.; Pitt, P. 1987: Aminoglutethimide in the treatment of advanced prostatic cancer Progress in Clinical and Biological Research 243a: 275-282
Mahler, C.; Verhelst, J.; Denis, L. 1996: New molecules and treatment modulation in advanced prostatic cancer Acta Urologica Belgica 64(2): 95-98
Jönsson, G. 1971: Continued experiences with Estracyt in the treatment of advanced prostatic cancer Nordisk Medicin 85(6): 186-187
Levin, M.; Pandya, K.J.; Khandekar, J.D.; Horton, J.; Glick, J.H.; Bennett, J.M.; Muggia, F.M.; Falkson, G. 1984: Phase Ii study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 68(12): 1511-1512
Nagel, R. 1980: Practical limitations of a controlled multicenter therapeutic study with the example of advanced inoperable prostatic cancer Verhandlungen der Deutschen Gesellschaft für Innere Medizin 86: 1304-1316
Shirahama, S.; Aritomi, T.; Takeo, S.; Ando, K.; Wakamatsu, S.-i.; Kumagawa, M.; Ichinose, I.; Tamura, K. 2004: Pilot study-previously treated advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(13): 2133-2137
Kamata, T.; Hayashi, Y.; Minatoya, G.; Michiwa, Y.; Onishi, I.; Takeda, T.; Koyasaki, N.; Kanno, M. 2001: A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(10): 1419-1422
Williams, C.J.; Barley, V.; Blackledge, G.; Hutcheon, A.; Kaye, S.; Smith, D.; Keen, C.; Webster, D.J.; Rowland, C.; Tyrrell, C. 1987: Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer Cancer Treatment Reports 71(12): 1197-1201
Takahashi, T.; Saikawa, Y.; Yoshida, M.; Kitagawa, Y.; Otani, Y.; Kubota, T.; Kumai, K.; Kitajima, M. 2006: A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer Anticancer Research 26(2b): 1631-1635
Bolis, G. 1995: Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer Seminars in Oncology 22(6 Suppl 14: 32-34
Yoshimatsu, K.; Yokomizo, H.; Fujimoto, T.; Umehara, A.; Otani, T.; Matsumoto, A.; Osawa, G.; Ogawa, K. 2007: Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer Anticancer Research 27(3b): 1657-1661
Bunn, P.A. 1999: Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer Seminars in Oncology 26(1 Suppl 4: 25-30
Abou-Mourad, Y.; Otrock, Z.K.; Makarem, J.A.; Kattan, J.G.; Farhat, F.S.; Jalloul, R.; Mokaddem, W.T.; Ghosen, M.G.; Taher, A.T.; Chehal, A.A.; Shamseddine, A.I. 2008: Docetaxel and irinotecan as first-line chemotherapy in patients with advanced non-small-cell lung cancer: a pilot study Le Journal Medical Libanais. Lebanese Medical Journal 56(1): 16-21
Labrie, F.; Dupont, A.; Giguère, M.; Borsanyi, J.P.; Lacourciere, Y.; Bélanger, A.; Lachance, R.; Emond, J.; Monfette, G. 1988: Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer Progress in Clinical and Biological Research 260: 41-62
Wechsel, H.W.; Zerbib, M.; Pagano, F.; Coptcoat, M.J. 1996: Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer European Urology 30(Suppl): 7